Quince Therapeutics (QNCX) Non-Current Debt (2023 - 2025)
Quince Therapeutics (QNCX) posted quarterly Non-Current Debt of $17.0 million for Q2 2025, up 22.81% year-over-year from $13.8 million in Q2 2024, and up 11.29% quarter-over-quarter from $15.3 million in Q1 2025.
Quince Therapeutics (QNCX) Non-Current Debt (2023 - 2025) Analysis & Trends
Quince Therapeutics' Non-Current Debt history runs 3 years deep, the most recent figure standing at $17.0 million for Q2 2025.
- In Q2 2025, Non-Current Debt rose 22.81% year-over-year to $17.0 million; the TTM figure through Jun 2025 stood at $17.0 million (up 22.81% YoY), while the FY2024 annual figure was $14.3 million, up 6.64% from the prior year.
- Non-Current Debt for Q2 2025 stood at $17.0 million, up from $15.3 million in the prior quarter.
- The five-year high for Non-Current Debt was $17.0 million in Q2 2025, with the low at $13.4 million in Q4 2023.
- The 3-year median for Non-Current Debt is $14.3 million (2024), against an average of $14.6 million.
- The sharpest annual moves came in 2024 and 2025: Non-Current Debt advanced 6.64% in 2024, then advanced 22.81% in 2025.
- Quince Therapeutics' Non-Current Debt stood at $13.4 million in 2023, then rose by 6.64% to $14.3 million in 2024, then increased by 18.63% to $17.0 million in 2025.
- Business Quant data shows QNCX's Non-Current Debt at $17.0 million in Q2 2025, $15.3 million in Q1 2025, and $14.3 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.97 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 8.96 Bn |
| 10 | Quince Therapeutics | 203.43 Mn | 203.43 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 16.99 Mn |
| Mar 31, 2025 | 15.27 Mn |
| Dec 31, 2024 | 14.32 Mn |
| Sep 30, 2024 | 14.90 Mn |
| Jun 30, 2024 | 13.83 Mn |
| Mar 31, 2024 | 13.52 Mn |
| Dec 31, 2023 | 13.43 Mn |